On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. This makes Zepbound the only drug in history to be approved specifically for OSA — a condition that affects an estimated 30 million Americans and has, until now, been treated almost exclusively with devices rather than medications.

For patients at BeLite who are already taking Zepbound for weight management, this approval carries an important clinical message: the medication may be doing more than helping you lose weight. It may be directly improving — or even resolving — a serious sleep disorder at the same time.

What Is Obstructive Sleep Apnea — and Why Obesity Drives It

Obstructive sleep apnea is a disorder in which the upper airway collapses repeatedly during sleep, causing breathing to pause — sometimes dozens or even hundreds of times per night. Each episode briefly starves the body of oxygen, triggering a micro-arousal that fragments sleep. Patients often don’t remember these awakenings, but wake feeling unrefreshed and struggle with daytime fatigue, difficulty concentrating, and mood disturbances.

The standard measure of OSA severity is the Apnea-Hypopnea Index (AHI), which counts the number of breathing interruptions per hour of sleep:

 

AHI (events/hour)	OSA Severity
5–14	Mild
15–29	Moderate
≥30	Severe

 

Obesity is a primary driver of OSA because excess adipose tissue — particularly around the neck, tongue, and soft palate — narrows the upper airway and increases its tendency to collapse during the muscle relaxation of sleep. The connection is direct: for every 10% increase in body weight, OSA risk rises approximately six-fold. Conversely, weight loss has long been known to improve OSA, but achieving and sustaining meaningful weight loss without surgery has historically been extremely difficult.

Until December 2024, no medication had ever been FDA-approved to treat OSA. The standard of care has been continuous positive airway pressure (CPAP) therapy — a device worn during sleep that keeps the airway open via pressurized airflow. CPAP is effective, but compliance is a significant clinical challenge: many patients find the mask uncomfortable, claustrophobic, or disruptive to sleep, and adherence rates are often below 50% in real-world settings. CPAP also does not address the underlying cause — obesity — in any way.

The SURMOUNT-OSA Trial: What the Evidence Shows

The FDA approval was based on results from SURMOUNT-OSA, a Phase 3 clinical trial program published in the New England Journal of Medicine in June 2024. The trial enrolled 469 adults with moderate-to-severe OSA (AHI ≥ 15 events/hour) and obesity (BMI ≥ 30 kg/m²). Participants were randomized 1:1 to receive tirzepatide (at their maximum tolerated dose of 10 or 15 mg once weekly) or placebo for 52 weeks, along with lifestyle counseling and a reduced-calorie diet. [Malhotra et al., N Engl J Med 2024; PMID 38912654]

The trial was designed as two parallel studies to address two distinct patient populations:

• Trial 1 (Study 5): Patients unable or unwilling to use PAP therapy — in other words, those for whom CPAP was not a realistic option.
• Trial 2 (Study 6): Patients already on PAP therapy who wanted an alternative or adjunct treatment.

 

The Primary Results

The results were striking in both groups. At week 52:

 

Outcome	Trial 1 (No PAP)	Trial 2 (On PAP)
Mean AHI reduction — tirzepatide	−25.3 events/hr	−29.3 events/hr
Mean AHI reduction — placebo	−5.3 events/hr	−5.5 events/hr
Treatment difference vs. placebo	−20.0 events/hr (P<0.001)	−23.8 events/hr (P<0.001)
Body weight reduction	~18% (~45 lbs)	~20% (~50 lbs)
Patients achieving near-normal AHI	Up to 50.2%	Up to 50.2%

 

To put these numbers in perspective: the average patient entering the trial had an AHI of approximately 51 events per hour — severe OSA. After one year of tirzepatide, many patients’ AHI dropped to the mild or even normal range. Up to half of all tirzepatide-treated patients achieved an AHI below 15 events per hour — the clinical threshold separating moderate from mild OSA.

Beyond AHI: Broader Health Improvements

The trial measured several cardiometabolic endpoints beyond AHI, and the results across all of them favored tirzepatide:

• Hypoxic burden: Significantly reduced. Hypoxic burden — the cumulative oxygen deprivation from sleep-disordered breathing — is a stronger predictor of cardiovascular mortality than AHI alone. Its reduction suggests real downstream cardiovascular benefit.
• Systolic blood pressure: Reduced by 7.6–9.6 mmHg — a clinically meaningful decrease that compounds the cardiovascular benefit of weight loss alone.
• High-sensitivity C-reactive protein (hsCRP): Reduced by 40–50%, reflecting a major reduction in systemic inflammation, which is both a cause and consequence of OSA.
• Patient-reported outcomes: Tirzepatide-treated patients reported significantly improved sleep quality, reduced daytime sleepiness (Epworth Sleepiness Scale), and better health-related quality of life across multiple validated instruments.

 

What This Means for Different Patients

If You Cannot Tolerate CPAP

Until this approval, patients who couldn’t use CPAP had very limited options — dental appliances (less effective), positional therapy (works only for mild positional OSA), or surgery (invasive, not universally appropriate). Zepbound now represents the first pharmacological alternative. Trial 1 was designed specifically for this population, and the results show that a meaningful portion of CPAP-intolerant patients can achieve clinically significant OSA improvement through weight-based treatment alone.

If You Are Already Using CPAP

Trial 2 showed that patients who added tirzepatide to their existing CPAP therapy achieved even greater AHI reductions than Trial 1 patients. For many patients, this could translate into a lower required CPAP pressure, better mask fit as neck circumference decreases, or — for a subset — eventual CPAP discontinuation after re-evaluation by their sleep physician. It is important to note that decisions about stopping CPAP should always be made in consultation with a sleep specialist following a formal sleep study or home sleep test.

The Cardiovascular Connection

Untreated OSA is not just a sleep problem. It is an independent risk factor for hypertension, atrial fibrillation, stroke, heart failure, and all-cause mortality. The repeated oxygen desaturations that occur during apnea episodes activate the sympathetic nervous system, increase blood pressure, trigger inflammatory cascades, and promote endothelial dysfunction. Treating OSA — whether through CPAP or, now, through tirzepatide-mediated weight loss — may therefore carry cardiovascular benefits that extend well beyond sleep quality. This is particularly relevant because Wegovy (semaglutide) has already demonstrated a cardiovascular mortality benefit in the SELECT trial, and research into tirzepatide’s cardiovascular outcomes is ongoing.

Who Is Eligible for Zepbound’s Sleep Apnea Indication?

The FDA approval is specifically for adults with:

• Moderate-to-severe OSA: Defined as an AHI ≥ 15 events per hour, confirmed by a sleep study
• Obesity: BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with a weight-related comorbidity in some clinical contexts)

 

Zepbound for sleep apnea is intended to be used in combination with a reduced-calorie diet and increased physical activity — the same lifestyle framework recommended for weight management.

Standard Zepbound contraindications apply regardless of indication:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to tirzepatide
• Current use of other tirzepatide-containing products or any GLP-1 receptor agonist

 

Patients on oral contraceptives should be aware that tirzepatide may lower their blood levels (due to delayed gastric emptying affecting absorption) and should discuss this with their prescriber.

What This Means for BeLite Patients

Many patients who seek care at BeLite for weight management have undiagnosed or undertreated OSA. The connection is not coincidental — obesity is the most modifiable risk factor for OSA, and the two conditions reinforce each other: poor sleep quality promotes weight gain by disrupting the hormones that regulate appetite, and excess weight worsens breathing during sleep.

 

A documented history of OSA can improve the chances of your insurance company covering the use of zepbound for weight loss.

If you are currently taking Zepbound at BeLite and have ever been told you snore heavily, have been diagnosed with OSA, or experience persistent daytime fatigue despite adequate sleep hours, this approval is directly relevant to you. As you lose weight on Zepbound, your OSA severity may be improving in parallel — even if you haven’t been formally re-evaluated by a sleep specialist.

Conversely, if you have OSA and have not been prescribed Zepbound, this approval opens a new treatment pathway that your BeLite provider can now discuss with you.

BeLite providers do not diagnose or manage OSA directly — that requires a sleep study and evaluation by a sleep medicine specialist or pulmonologist. However, we can help you understand the connection between your weight loss progress and your sleep health, and coordinate with your other providers as your body composition improves.

 

 

 

Related BeLite Blog Posts

1. Tirzepatide vs. Semaglutide: Which Weight Loss Drug Works Better? — 2025 NEJM Study Explained
2. Comparing Wegovy and Zepbound in Non-Diabetic Patients — Which Is Best for You?
3. How to Maximize Weight Loss Success for Patients on Zepbound or Wegovy
4. Wegovy 7.2 mg vs. Zepbound: How GLP-1 Therapy Evolved from 15% to 20% Weight Loss
5. Zepbound Side Effects: Common, Serious & How to Manage Them

 

Medical Disclaimer: This blog post is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to substitute for consultation with a licensed healthcare provider. Decisions about sleep apnea diagnosis, CPAP discontinuation, and medication management should be made in consultation with qualified medical professionals. Dr. Rothman is the Medical Director of BeLite Medical Center, which has been helping patients lose weight in the Northern Virginia area since 1995.